BIIB vs LLY: Side-by-Side Comparison
Compare Biogen Inc (BIIB) and Lilly(Eli) & Company (LLY) side by side: market cap USD 31.91B vs USD 1.08T, P/E 23.2 vs 43.7. Financials, growth and model signals on Bullrun.
| Metric | BIIB | LLY |
|---|---|---|
| Company | Biogen Inc | Lilly(Eli) & Company |
| Country / Exchange | United States · NASDAQ | United States · NYSE |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers-General | Drug Manufacturers-General |
| Market cap | USD 31.91B | USD 1.08T |
| P/E ratio | 23.2 | 43.7 |
| Dividend yield | — | 0.53% |
| Valuation model | 5.7% undervalued | 11.4% overvalued |
| Revenue (FY2025) | USD 9.89B | USD 65.18B |
| Revenue growth YoY | +2.2% | +44.7% |
| Net income | USD 1.29B | USD 20.64B |
| Gross margin | 75.7% | 83.0% |
| Diluted EPS | 8.79 | 22.95 |